Compile Data Set for Download or QSAR
Report error Found 3309 for UniProtKB: P68400
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50437434(CHEMBL2409175)
Affinity DataKd:  0.00500nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50172243(CHEMBL3103192)
Affinity DataKd:  0.00600nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010980(CHEMBL4089961)
Affinity DataKd:  0.0160nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010980(CHEMBL4089961)
Affinity DataKd:  0.0160nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010942(CHEMBL4077554)
Affinity DataKd:  0.0370nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010942(CHEMBL4077554)
Affinity DataKd:  0.0370nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50172246(CHEMBL3103191)
Affinity DataKd:  0.0480nMAssay Description:Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50040717(CHEMBL4099729)
Affinity DataKd:  0.0933nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50040717(CHEMBL4099729)
Affinity DataKd:  0.0940nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha/beta(Human)
Senhwa Biosciences

US Patent
LigandPNGBDBM218843(US9303033, A1, Example 5)
Affinity DataIC50: 0.100nMpH: 7.2Assay Description:In a final reaction volume of 50 μl, CK2 ααββ (4 ng, 8.5 mU) was incubated with various concentrations of test compounds in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2017
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142829(US8940736, 391)
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142817(US8940736, 285)
Affinity DataIC50: 0.140nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644447(US11866436, Example 41 | 5-((2-(4-((3-cyano-4- cyc...)
Affinity DataIC50: 0.145nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142774(US8940736, 6)
Affinity DataIC50: 0.150nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142835(US8940736, 402)
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010975(CHEMBL4075338)
Affinity DataKd:  0.162nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50010975(CHEMBL4075338)
Affinity DataKd:  0.170nMAssay Description:Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2020
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142775(US8940736, 7)
Affinity DataIC50: 0.170nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644585((R)-5-((1-(4-((3-fluoro-4-(trifluoromethoxy)benzyl...)
Affinity DataIC50: 0.180nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644445(US11866436, Example 39 | 5-((2-(4-((3-cyano-4- cyc...)
Affinity DataIC50: 0.197nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644580(5-((2-(4-((3-((1H-pyrazol-4-yl)methyl)-5-(trifluor...)
Affinity DataIC50: 0.201nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644448(US11866436, Example 42 | 5-((2-(4-((3-chloro- 5-(c...)
Affinity DataIC50: 0.203nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142793(US8940736, 161)
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142806(US8940736, 229)
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644564(5-((2-(4-((3- (oxazol-5- ylmethyl)-5- (trifluorome...)
Affinity DataIC50: 0.217nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142784(US8940736, 117)
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142832(US8940736, 395)
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644439(US11866436, Example 33 | 5-((2-(4-((3-Chloro-4-cyc...)
Affinity DataIC50: 0.221nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644578(5-((2-(4-((3- (furan-3- ylmethyl)-5- (trifluoromet...)
Affinity DataIC50: 0.223nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142834(US8940736, 399)
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142777(US8940736, 49)
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644583(5-((2-(4- ((3,5- difluoro-4- (trifluoro- methoxy) ...)
Affinity DataIC50: 0.236nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142792(US8940736, 160)
Affinity DataIC50: 0.240nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644417(US11866436, Example 11 | 5-((2-(4-((3-chloro-4- (c...)
Affinity DataIC50: 0.244nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644440(US11866436, Example 34 | 5-((2-(4-((3-chloro-4- cy...)
Affinity DataIC50: 0.248nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644520(US11866436, Example 115 | 5-(2-(4-((3- bromo-5- (t...)
Affinity DataIC50: 0.248nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644506(US11866436, Example 101 | 5-(3-(4-((3- fluoro-4- (...)
Affinity DataIC50: 0.258nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50214466(N-(3-(8-cyano-4-(cyclopropylamino)pyrazolo[1,5-a][...)
Affinity DataKi:  0.260nMAssay Description:Inhibition of human CK2 alphaMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644511(US11866436, Example 106 | 5-((2-(4-((3- chloro-5- ...)
Affinity DataIC50: 0.263nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644577(5-((2-(4-((3- ((1H-imidazol- 1-yl)methyl)-5- (trif...)
Affinity DataIC50: 0.265nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142831(US8940736, 394)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142816(US8940736, 281)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142794(US8940736, 163)
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644426(US11866436, Example 20 | 5-((2-(4-((3- cyano-4- cy...)
Affinity DataIC50: 0.278nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142820(US8940736, 319)
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142818(US8940736, 313)
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142778(US8940736, 55)
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha [2-329](Human)
Cambridge Enterprise

US Patent
LigandPNGBDBM644409(US11866436, Example 3 | 5-((2-(4-((3-chloro- 4-(tr...)
Affinity DataIC50: 0.298nMAssay Description:Final assay conditions comprised 0.2 nM CK2α, 50 μM peptide substrate (RRRADDSDDDDD), 15 μM ATP in 1× reaction buffer (40 mM Tris pH7....More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142779(US8940736, 57)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

TargetCasein kinase II subunit alpha(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM142795(US8940736, 167)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2015
Entry Details
US Patent

Displayed 1 to 50 (of 3309 total ) | Next | Last >>
Jump to: